341 related articles for article (PubMed ID: 30325535)
1. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of ferritin subunits expression and positive correlations with tumor-associated macrophages and T regulatory cells infiltration in most solid tumors.
Hu ZW; Chen L; Ma RQ; Wei FQ; Wen YH; Zeng XL; Sun W; Wen WP
Aging (Albany NY); 2021 Apr; 13(8):11491-11506. PubMed ID: 33864445
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
Tachibana T; Andou T; Tanaka M; Ito S; Miyazaki T; Ishii Y; Ogusa E; Koharazawa H; Takahashi H; Motohashi K; Aoki J; Nakajima Y; Matsumoto K; Hagihara M; Hashimoto C; Taguchi J; Fujimaki K; Fujita H; Fujisawa S; Kanamori H; Nakajima H;
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):415-421. PubMed ID: 29673622
[TBL] [Abstract][Full Text] [Related]
4. Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration.
Muhoberac BB; Baraibar MA; Vidal R
Biochim Biophys Acta; 2011 Apr; 1812(4):544-8. PubMed ID: 21029774
[TBL] [Abstract][Full Text] [Related]
5. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
6. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
8. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.
Lebon D; Vergez F; Bertoli S; Harrivel V; De Botton S; Micol JB; Marolleau JP; Récher C
Leuk Res; 2015 Aug; 39(8):818-21. PubMed ID: 26002512
[TBL] [Abstract][Full Text] [Related]
9. Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
Tyagi A; Pramanik R; Bakhshi R; Singh A; Vishnubhatla S; Bakhshi S
Int J Hematol; 2019 Aug; 110(2):205-212. PubMed ID: 31119613
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone in hyperleukocytic acute myeloid leukemia.
Bertoli S; Picard M; Bérard E; Griessinger E; Larrue C; Mouchel PL; Vergez F; Tavitian S; Yon E; Ruiz J; Delabesse E; Luquet I; Linares LK; Saland E; Carroll M; Danet-Desnoyers G; Sarry A; Huguet F; Sarry JE; Récher C
Haematologica; 2018 Jun; 103(6):988-998. PubMed ID: 29519869
[TBL] [Abstract][Full Text] [Related]
11. Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma.
Huang H; Qiu Y; Huang G; Zhou X; Zhou X; Luo W
Med Sci Monit; 2019 May; 25():3700-3715. PubMed ID: 31104064
[TBL] [Abstract][Full Text] [Related]
12. AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
Ihlow J; Gross S; Sick A; Schneider T; Flörcken A; Burmeister T; Türkmen S; Arnold R; Dörken B; Westermann J
Leuk Lymphoma; 2019 Jan; 60(1):69-77. PubMed ID: 29846127
[TBL] [Abstract][Full Text] [Related]
13. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
[TBL] [Abstract][Full Text] [Related]
14. Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
Nibourel O; Guihard S; Roumier C; Pottier N; Terre C; Paquet A; Peyrouze P; Geffroy S; Quentin S; Alberdi A; Abdelali RB; Renneville A; Demay C; Celli-Lebras K; Barbry P; Quesnel B; Castaigne S; Dombret H; Soulier J; Preudhomme C; Cheok MH
Leukemia; 2017 Mar; 31(3):555-564. PubMed ID: 27686867
[TBL] [Abstract][Full Text] [Related]
15. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
[TBL] [Abstract][Full Text] [Related]
16. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
[TBL] [Abstract][Full Text] [Related]
17. High Expression of VAV Gene Family Predicts Poor Prognosis of Acute Myeloid Leukemia.
Mu D; Long S; Guo L; Liu W
Technol Cancer Res Treat; 2021; 20():15330338211065877. PubMed ID: 34894858
[No Abstract] [Full Text] [Related]
18. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
[TBL] [Abstract][Full Text] [Related]
20. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
